Metformin as a Novel Component of Metronomic Chemotherapeutic Use: A Hypothesis

Journal of Experimental and Clinical Medicine

Volumn 4, Issue 3, 2012, Pages 140-144

  Duque, Jorge Eduardo ^a,b   Velez, Juliana ^a   Samudio, Ismael ^a   Lai, Enoch ^c  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b Centro Oncológico de Antioquia   (Colombia)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AMPK; Cancer; Metabolism; Metformin; Metronomic chemotherapy

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; METFORMIN;

ANTINEOPLASTIC ACTIVITY; BREAST ADENOCARCINOMA; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; DNA DAMAGE; DRUG ACTIVITY; DRUG EFFICACY; ENDOMETRIUM CARCINOMA; ENZYME ACTIVATION; HUMAN; IMMUNOMODULATION; MAXIMUM TOLERATED DOSE; METRONOMIC DRUG ADMINISTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OVARY POLYCYSTIC DISEASE; OXIDATIVE PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; TUMOR IMMUNITY;

EID: 84862016045     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2012.04.002     Document Type: Review

References (45)

1. Anisimov V.N., Berstein L.M., Egormin P.A., Piskunova T.S., Popovich I.G., Zabezhinski M.A., Kovalenko I.G., et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Exp Gerontol 2005, 40:685-693.
2. Wysocki P.J., Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn 2010, 10:509-519.
3. Motta A.B. Mechanisms involved in metformin action in the treatment of polycystic ovary syndrome. Curr Pharm Des 2009, 15:3074-3077.
4. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
5. Foretz M., Hébrard S., Leclerc J., Zarrinpashneh E., Soty M., Mithieux G., Sakamoto K., et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 2010, 120:2355-2369.
6. Sun Y., Fang Y., Yoon M.S., Zhang C., Roccio M., Zwartkruis F.J., Armstrong M., et al. Phospholipase D1 is an effector of Rheb in the mTOR pathway. Proc Natl Acad Sci U S A 2008, 105:8286-8291.
7. Zakikhani M., Blouin M.J., Piura E., Pollak M.N. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 2010, 123:271-279.
8. Han S., Khuri F.R., Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 2006, 66:315-323.
9. Dowling R.J., Zakikhani M., Fantus I.G., Pollak M., Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 2007, 67:10804-10812.
10. Vazquez-Martin A., Oliveras-Ferraros C., Menendez J.A. The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 2009, 8:88-96.
11. Ben S.I., Laurent K., Loubat A., Giorgetti-Peraldi S., Colosetti P., Auberger P., Tanti J.F., et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 2008, 27:3576-3586.
12. Luo Z., Zang M., Guo W. AMPK as a metabolic tumor suppressor: control of metabolism and cell growth. Future Oncol 2010, 6:457-470.
13. Cao C., Lu S., Kivlin R., Wallin B., Card E., Bagdasarian A., Tamakloe T., et al. SIRT1 confers protection against UVB- and H2O2-induced cell death via modulation of p53 and JNK in cultured skin keratinocytes. J Cell Mol Med 2009, 13:3632-3643.
14. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000, 348:607-614.
15. Kalender A., Selvaraj A., Kim S.Y., Gulati P., Brule S., Viollet B., Kemp B.E., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010, 11:390-401.
16. Rattan R., Giri S., Hartmann L., Shridhar V. Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner. Cell Mol Med 2011, 15:166-178.
17. Salpeter S.R., Greyber E., Pasternak G.A., Salpeter E.E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010, 4:CD002967.
18. Samudio I., Kurinna S., Ruvolo P., Korchin B., Kantarjian H., Beran M., Dunner K., et al. Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells. Mol Cancer Ther 2008, 7:1130-1139.
19. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., Dunner K., et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010, 120:142-156.
20. Samudio I., Konopleva M., Pelicano H., Huang P., Frolova O., Bornmann W., Ying Y., et al. A novel mechanism of action of methyl-2-cyano-3,12 dioxoolean-1,9 diene-28-oate (CDDO-Me): direct permeabilization of the inner mitochondrial membrane to inhibit electron transport and induce apoptosis. Mol Pharmacol 2006, 69:1182-1193.
21. Samudio I., Fiegl M., Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res 2009, 69:2163-2166.
22. Samudio I., Fiegl M., McQueen T., Clise-Dwyer K., Andreeff M. The Warburg effect in leukemia-stroma cocultures is mediated by mitochondrial uncoupling associated with uncoupling protein 2 activation. Cancer Res 2008, 68:5198-5205.
23. Garcia E.Y. Fluamine, a new synthetic analgesic and antiflu drug. J Philipp Med Assoc 1950, 26:287-293.
24. Pearce E.L., Walsh M.C., Cejas P.J., Harms G.M., Shen H., Wang L.S., Jones R.G., et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009, 460:103-107.
25. Ropelle E.R., Pauli J.R., Zecchin K.G., Ueno M., de Souza C.T., Morari J., Faria M.C., et al. A central role for neuronal adenosine 5'-monophosphate-activated protein kinase in cancer-induced anorexia. Endocrinology 2007, 148:5220-5229.
26. Landman G.W., Kleefstra N., van Hateren K.J., Groenier K.H., Gans R.O., Bilo H.J. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010, 33:322-326.
27. Wright J.L., Stanford J.L. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009, 20:1617-1622.
28. Li D., Yeung S.C., Hassan M.M., Konopleva M., Abbruzzese J.L. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009, 137:482-488.
29. Goodwin P.J., Ligibel J.A., Stambolic V. Metformin in breast cancer: time for action. J Clin Oncol 2009, 27:3271-3273.
30. Goodwin P.J., Pritchard K.I., Ennis M., Clemons M., Graham M., Fantus I.G. Insulin-lowering effects of metformin in women with early breast cancer. Clin Breast Cancer 2008, 8:501-505.
31. Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., Hartwick W., et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002, 20:42-51.
32. Jiralerspong S., Palla S.L., Giordano S.H., Meric-Bernstam F., Liedtke C., Barnett C.M., Hsu L., et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009, 27:3297-3302.
33. Stanosz S. An attempt at conservative treatment in selected cases of type I endometrial carcinoma (stage I a/G1) in young women. Eur J Gynaecol Oncol 2009, 30:365-369.
34. Hosono K., Endo H., Takahashi H., Sugiyama M., Sakai E., Uchiyama T., Suzuki K., et al. Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila) 2010, 3:1077-1083.
35. Gasparini G. Metronomic scheduling: the future of chemotherapy?. Lancet Oncol 2001, 2:733-740.
36. Pasquier E., Kavallaris M., Andre N. Metronomic chemotherapy: new rationale for new directions. Nat Rev Clin Oncol 2010, 7:455-465.
37. Moschetta M., Cesca M., Pretto F., Giavazzi R. Angiogenesis inhibitors: implications for combination with conventional therapies. Curr Pharm Des 2010, 16:3921-3931.
38. Folkman J. Tumor angiogenesis: role in regulation of tumor growth. Symp Soc Dev Biol 1974, 30:43-52.
39. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Ann Intern Med 1975, 82:96-100.
40. Drevs J., Fakler J., Eisele S., Medinger M., Bing G., Esser N., Marmé D., et al. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res 2004, 24:1759-1763.
41. Lam T., Hetherington J.W., Greenman J., Little S., Maraveyas A. Metronomic chemotherapy dosing-schedules with estramustine and temozolomide act synergistically with anti-VEGFR-2 antibody to cause inhibition of human umbilical venous endothelial cell growth. Acta Oncol 2007, 46:1169-1177.
42. Ooyama A., Oka T., Zhao H.Y., Yamamoto M., Akiyama S., Fukushima M. Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett 2008, 267:26-36.
43. Stoelting S., Trefzer T., Kisro J., Steinke A., Wagner T., Peters S.O. Low-dose oral metronomic chemotherapy prevents mobilization of endothelial progenitor cells into the blood of cancer patients. In Vivo 2008, 22:831-836.
44. Hanahan D., Bergers G., Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000, 105:1045-1047.
45. Kim H.G., Hien T.T., Han E.H., Hwang Y.P., Choi J.H., Kang K.W., Kwon K.I., et al. Metformin inhibits P-glycoprotein expression via the NF-kappaB pathway and CRE transcriptional activity through AMPK activation. Br J Pharmacol 2011, 162:1096-1108.